The term “non-alcoholic steatohepatitis” (NASH) was originally used to describe liver damage characterized by lobular inflammation, steatosis and ballooning of hepatocytes. In addition, a large proportion of patients were described as having “cryptogenic cirrhosis” at the time: The term “non-alcoholic fatty liver disease” (NAFLD) was established as the diagnosis for these patients.
Autoren
- PD Dr. med. Sena Blümel
- Prof. Dr. med. Christoph Jüngst
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Pneumococcal conjugate vaccine (PCV)
Best possible serotype coverage in the respective age group
- Psoriasis: intervening in the inflammatory cascade
Advantages of early biologic therapy and oral peptide as a beacon of hope
- AI-supported imaging and new biomarkers
CHD diagnostics update
- Bipolar disorder, anxiety disorder, depression
Lurasidone as monotherapy for bipolar I depression with anxiety symptoms
- Arterial hypertension: ESC guideline 2024 in focus
New category “elevated blood pressure” – what are the therapeutic implications?
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Low-grade pediatric gliomas
Consideration of the tumor microenvironment opens up new treatment options
- Patient-centered rounds in medicine